214 related articles for article (PubMed ID: 23541670)
41. Development, Optimization, and Structure-Activity Relationships of Covalent-Reversible JAK3 Inhibitors Based on a Tricyclic Imidazo[5,4- d]pyrrolo[2,3- b]pyridine Scaffold.
Forster M; Chaikuad A; Dimitrov T; Döring E; Holstein J; Berger BT; Gehringer M; Ghoreschi K; Müller S; Knapp S; Laufer SA
J Med Chem; 2018 Jun; 61(12):5350-5366. PubMed ID: 29852068
[TBL] [Abstract][Full Text] [Related]
42. Discovery and optimization of pyrrolo[1,2-a]pyrazinones leads to novel and selective inhibitors of PIM kinases.
Casuscelli F; Ardini E; Avanzi N; Casale E; Cervi G; D'Anello M; Donati D; Faiardi D; Ferguson RD; Fogliatto G; Galvani A; Marsiglio A; Mirizzi DG; Montemartini M; Orrenius C; Papeo G; Piutti C; Salom B; Felder ER
Bioorg Med Chem; 2013 Dec; 21(23):7364-80. PubMed ID: 24139169
[TBL] [Abstract][Full Text] [Related]
43. Novel 5,7-disubstituted 6-amino-5H-pyrrolo[3,2-b]pyrazine-2,3-dicarbonitriles, the promising protein kinase inhibitors with antiproliferative activity.
Dubinina GG; Platonov MO; Golovach SM; Borysko PO; Tolmachov AO; Volovenko YM
Eur J Med Chem; 2006 Jun; 41(6):727-37. PubMed ID: 16675067
[TBL] [Abstract][Full Text] [Related]
44. Phenylaminopyrimidines as inhibitors of Janus kinases (JAKs).
Burns CJ; Bourke DG; Andrau L; Bu X; Charman SA; Donohue AC; Fantino E; Farrugia M; Feutrill JT; Joffe M; Kling MR; Kurek M; Nero TL; Nguyen T; Palmer JT; Phillips I; Shackleford DM; Sikanyika H; Styles M; Su S; Treutlein H; Zeng J; Wilks AF
Bioorg Med Chem Lett; 2009 Oct; 19(20):5887-92. PubMed ID: 19762238
[TBL] [Abstract][Full Text] [Related]
45. Structure-based design and synthesis of 1H-pyrazolo[3,4-d]pyrimidin-4-amino derivatives as Janus kinase 3 inhibitors.
Yin Y; Chen CJ; Yu RN; Wang ZJ; Zhang TT; Zhang DY
Bioorg Med Chem; 2018 Sep; 26(17):4774-4786. PubMed ID: 30139575
[TBL] [Abstract][Full Text] [Related]
46. VX-509 (decernotinib) is a potent and selective janus kinase 3 inhibitor that attenuates inflammation in animal models of autoimmune disease.
Mahajan S; Hogan JK; Shlyakhter D; Oh L; Salituro FG; Farmer L; Hoock TC
J Pharmacol Exp Ther; 2015 May; 353(2):405-14. PubMed ID: 25762693
[TBL] [Abstract][Full Text] [Related]
47. ATP-mediated kinome selectivity: the missing link in understanding the contribution of individual JAK Kinase isoforms to cellular signaling.
Thorarensen A; Banker ME; Fensome A; Telliez JB; Juba B; Vincent F; Czerwinski RM; Casimiro-Garcia A
ACS Chem Biol; 2014 Jul; 9(7):1552-8. PubMed ID: 24814050
[TBL] [Abstract][Full Text] [Related]
48. Synthesis and biological activity of pyridopyridazin-6-one p38 MAP kinase inhibitors. Part 1.
Tynebor RM; Chen MH; Natarajan SR; O'Neill EA; Thompson JE; Fitzgerald CE; O'Keefe SJ; Doherty JB
Bioorg Med Chem Lett; 2011 Jan; 21(1):411-6. PubMed ID: 21084192
[TBL] [Abstract][Full Text] [Related]
49. Identification of pyrrolo[2,3-g]indazoles as new Pim kinase inhibitors.
Gavara L; Suchaud V; Nauton L; Théry V; Anizon F; Moreau P
Bioorg Med Chem Lett; 2013 Apr; 23(8):2298-301. PubMed ID: 23499503
[TBL] [Abstract][Full Text] [Related]
50. The discovery of potent and selective 4-aminothienopyridines as B-Raf kinase inhibitors.
Tang J; Lackey KE; Dickerson SH
Bioorg Med Chem Lett; 2013 Jan; 23(1):66-70. PubMed ID: 23218715
[TBL] [Abstract][Full Text] [Related]
51. A combination strategy to inhibit Pim-1: synergism between noncompetitive and ATP-competitive inhibitors.
Mori M; Tintori C; Christopher RS; Radi M; Schenone S; Musumeci F; Brullo C; Sanità P; Delle Monache S; Angelucci A; Kissova M; Crespan E; Maga G; Botta M
ChemMedChem; 2013 Mar; 8(3):484-96. PubMed ID: 23436791
[TBL] [Abstract][Full Text] [Related]
52. Discovery and optimization of potent and selective imidazopyridine and imidazopyridazine mTOR inhibitors.
Peterson EA; Boezio AA; Andrews PS; Boezio CM; Bush TL; Cheng AC; Choquette D; Coats JR; Colletti AE; Copeland KW; DuPont M; Graceffa R; Grubinska B; Kim JL; Lewis RT; Liu J; Mullady EL; Potashman MH; Romero K; Shaffer PL; Stanton MK; Stellwagen JC; Teffera Y; Yi S; Cai T; La DS
Bioorg Med Chem Lett; 2012 Aug; 22(15):4967-74. PubMed ID: 22765895
[TBL] [Abstract][Full Text] [Related]
53. Discovery of diaminopyrimidine-carboxamide derivatives as JAK3 inhibitors.
Bahekar R; Panchal N; Soman S; Desai J; Patel D; Argade A; Gite A; Gite S; Patel B; Kumar J; S S; Patel H; Sundar R; Chatterjee A; Mahapatra J; Patel H; Ghoshdastidar K; Bandyopadhyay D; Desai RC
Bioorg Chem; 2020 Jun; 99():103851. PubMed ID: 32334196
[TBL] [Abstract][Full Text] [Related]
54. Discovery of novel Bruton's tyrosine kinase (BTK) inhibitors bearing a pyrrolo[2,3-d]pyrimidine scaffold.
Zhao X; Huang W; Wang Y; Xin M; Jin Q; Cai J; Tang F; Zhao Y; Xiang H
Bioorg Med Chem; 2015 Feb; 23(4):891-901. PubMed ID: 25596757
[TBL] [Abstract][Full Text] [Related]
55. Synthetic staurosporines via a ring closing metathesis strategy as potent JAK3 inhibitors and modulators of allergic responses.
Wilson LJ; Malaviya R; Yang C; Argentieri R; Wang B; Chen X; Murray WV; Cavender D
Bioorg Med Chem Lett; 2009 Jun; 19(12):3333-8. PubMed ID: 19427203
[TBL] [Abstract][Full Text] [Related]
56. Discovery of 7-(3-(piperazin-1-yl)phenyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine derivatives as highly potent and selective PI3Kδ inhibitors.
Qin LY; Ruan Z; Cherney RJ; Dhar TGM; Neels J; Weigelt CA; Sack JS; Srivastava AS; Cornelius LAM; Tino JA; Stefanski K; Gu X; Xie J; Susulic V; Yang X; Yarde-Chinn M; Skala S; Bosnius R; Goldstein C; Davies P; Ruepp S; Salter-Cid L; Bhide RS; Poss MA
Bioorg Med Chem Lett; 2017 Feb; 27(4):855-861. PubMed ID: 28108251
[TBL] [Abstract][Full Text] [Related]
57. Design, synthesis and evaluation of pyrrolo[2,3-d]pyrimidine-phenylamide hybrids as potent Janus kinase 2 inhibitors.
Wang T; Liu X; Hao M; Qiao J; Ju C; Xue L; Zhang C
Bioorg Med Chem Lett; 2016 Jun; 26(12):2936-2941. PubMed ID: 27130359
[TBL] [Abstract][Full Text] [Related]
58. Discovery of 5-substituted-N-arylpyridazinones as inhibitors of p38 MAP kinase.
Jerome KD; Hepperle ME; Walker JK; Xing L; Devraj RV; Benson AG; Baldus JE; Selness SR
Bioorg Med Chem Lett; 2010 May; 20(10):3146-9. PubMed ID: 20395140
[TBL] [Abstract][Full Text] [Related]
59. Structure-activity relationships for a novel series of thiazolyl phenyl ether derivatives exhibiting potent and selective acetyl-CoA carboxylase 2 inhibitory activity.
Clark RF; Zhang T; Xin Z; Liu G; Wang Y; Hansen TM; Wang X; Wang R; Zhang X; Frevert EU; Camp HS; Beutel BA; Sham HL; Gu YG
Bioorg Med Chem Lett; 2006 Dec; 16(23):6078-81. PubMed ID: 16973360
[TBL] [Abstract][Full Text] [Related]
60. N-phenyl-N'-[4-(5H-pyrrolo[3,2-d]pyrimidin-4-yloxy)phenyl]ureas as novel inhibitors of VEGFR and FGFR kinases.
Oguro Y; Miyamoto N; Takagi T; Okada K; Awazu Y; Miki H; Hori A; Kamiyama K; Imamura S
Bioorg Med Chem; 2010 Oct; 18(20):7150-63. PubMed ID: 20833551
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
